Skip to content

Study · Animal study (in vivo) · hamster and mouse · 2026

23 results

Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.

Briand F, Le Cudennec C, Grasset E, Breyner N, Bigot C, Dillard P, Sulpice T

Obesity (Silver Spring, Md.)25 Feb 2026Cited by 3 (Europe PMC)

PMID41741376 (opens in a new tab)PMCIDPMC13250738 (opens in a new tab)DOI10.1002/oby.70155 (opens in a new tab)PepBankPUB-41741376
Download PDFPubMedAsk about this study
Jump to 23 results

Summary

Objective/methodsOur aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.ResultsIn mice, retatrutide strongly reduced body weight by 31% (p < 0.0001 vs. vehicle), both fat and lean mass, and food and water intake during the first days of treatment, while energy expenditure was not altered significantly. Retatrutide markedly reduced the HOMA-IR index of insulin resistance, hepatic steatosis score, fatty acids, triglycerides, and total cholesterol content. In hamsters, retatrutide altered food preference with increased chow diet intake and decreased high fat/cholesterol diet and 10% fructose water intake. The significant weight loss was associated with a reduction in fat and lean mass, but the lean mass was not different after 5 weeks of treatment with no change in mineral bone density. Retatrutide significantly reduced HOMA-IR, plasma triglycerides, and LDL-cholesterol levels. Although retatrutide did not reduce histopathological scoring, there was a 50% reduction in hepatic triglyceride content (p < 0.01).ConclusionsRetatrutide demonstrates multiple metabolic benefits in both mouse and hamster models. Our preclinical setting will help to assess the efficacy of novel therapies targeting obesity and MASH.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study23

23 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH mice, retatrutide reduced body weight by 31% versus vehicle.

    In plain wordsIn obese mice, retatrutide lowered body weight more than vehicle.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody weight (mice)
    Study

    mousen: not reported in source

    Diet-induced obese MASH mouse model
    Comparator
    Vehicle
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Body weight reduction
    31%
    vs vehicle

    Source sentences

    Summary
    In mice, retatrutide strongly reduced body weight by 31% (p < 0.0001 vs. vehicle), both fat and lean mass, and food and water intake during the first days of treatment, while energy expenditure was not altered significantly.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH mice, retatrutide reduced fat mass.

    In plain wordsIn obese mice, retatrutide lowered fat mass.

    Peptide
    Retatrutide
    Outcome
    DecreaseFat mass (mice)
    Study

    mousen: not reported in source

    Diet-induced obese MASH mouse model
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In mice, retatrutide strongly reduced body weight by 31% (p < 0.0001 vs. vehicle), both fat and lean mass, and food and water intake during the first days of treatment, while energy expenditure was not altered significantly.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH mice, retatrutide reduced lean mass.

    In plain wordsIn obese mice, retatrutide lowered lean mass.

    Peptide
    Retatrutide
    Outcome
    DecreaseLean mass (mice)
    Study

    mousen: not reported in source

    Diet-induced obese MASH mouse model
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In mice, retatrutide strongly reduced body weight by 31% (p < 0.0001 vs. vehicle), both fat and lean mass, and food and water intake during the first days of treatment, while energy expenditure was not altered significantly.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH mice, retatrutide reduced food intake during the first days of treatment.

    In plain wordsIn obese mice, retatrutide lowered food intake in the first days of treatment.

    Peptide
    Retatrutide
    Outcome
    DecreaseFood intake (mice)
    Study

    mousen: not reported in source

    Diet-induced obese MASH mouse model
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In mice, retatrutide strongly reduced body weight by 31% (p < 0.0001 vs. vehicle), both fat and lean mass, and food and water intake during the first days of treatment, while energy expenditure was not altered significantly.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH mice, retatrutide reduced water intake during the first days of treatment.

    In plain wordsIn obese mice, retatrutide lowered water intake in the first days of treatment.

    Peptide
    Retatrutide
    Outcome
    DecreaseWater intake (mice)
    Study

    mousen: not reported in source

    Diet-induced obese MASH mouse model
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In mice, retatrutide strongly reduced body weight by 31% (p < 0.0001 vs. vehicle), both fat and lean mass, and food and water intake during the first days of treatment, while energy expenditure was not altered significantly.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH mice, retatrutide did not significantly alter energy expenditure.

    In plain wordsIn obese mice, retatrutide did not significantly change energy expenditure.

    Peptide
    Retatrutide
    Outcome
    No significant changeEnergy expenditure (mice)
    Study

    mousen: not reported in source

    Diet-induced obese MASH mouse model
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In mice, retatrutide strongly reduced body weight by 31% (p < 0.0001 vs. vehicle), both fat and lean mass, and food and water intake during the first days of treatment, while energy expenditure was not altered significantly.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH mice, retatrutide markedly reduced the HOMA-IR index of insulin resistance.

    In plain wordsIn obese mice, retatrutide markedly lowered an insulin resistance index.

    Peptide
    Retatrutide
    Outcome
    DecreaseHOMA-IR (mice)
    Study

    mousen: not reported in source

    Diet-induced obese MASH mouse model
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Retatrutide markedly reduced the HOMA-IR index of insulin resistance, hepatic steatosis score, fatty acids, triglycerides, and total cholesterol content.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH mice, retatrutide markedly reduced the hepatic steatosis score.

    In plain wordsIn obese mice, retatrutide markedly lowered liver fat score.

    Peptide
    Retatrutide
    Outcome
    DecreaseHepatic steatosis score (mice)
    Study

    mousen: not reported in source

    Diet-induced obese MASH mouse model
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Retatrutide markedly reduced the HOMA-IR index of insulin resistance, hepatic steatosis score, fatty acids, triglycerides, and total cholesterol content.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH mice, retatrutide markedly reduced fatty acids.

    In plain wordsIn obese mice, retatrutide markedly lowered fatty acids.

    Peptide
    Retatrutide
    Outcome
    DecreaseFatty acids (mice)
    Study

    mousen: not reported in source

    Diet-induced obese MASH mouse model
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Retatrutide markedly reduced the HOMA-IR index of insulin resistance, hepatic steatosis score, fatty acids, triglycerides, and total cholesterol content.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH mice, retatrutide markedly reduced triglycerides.

    In plain wordsIn obese mice, retatrutide markedly lowered triglycerides.

    Peptide
    Retatrutide
    Outcome
    DecreaseTriglycerides (mice)
    Study

    mousen: not reported in source

    Diet-induced obese MASH mouse model
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Retatrutide markedly reduced the HOMA-IR index of insulin resistance, hepatic steatosis score, fatty acids, triglycerides, and total cholesterol content.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH mice, retatrutide markedly reduced total cholesterol content.

    In plain wordsIn obese mice, retatrutide markedly lowered total cholesterol.

    Peptide
    Retatrutide
    Outcome
    DecreaseTotal cholesterol (mice)
    Study

    mousen: not reported in source

    Diet-induced obese MASH mouse model
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Retatrutide markedly reduced the HOMA-IR index of insulin resistance, hepatic steatosis score, fatty acids, triglycerides, and total cholesterol content.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH hamsters, retatrutide increased chow diet intake.

    In plain wordsIn obese hamsters, retatrutide increased chow intake.

    Peptide
    Retatrutide
    Outcome
    IncreaseChow diet intake (hamsters)
    Study

    hamstern: not reported in source

    Diet-induced obese MASH hamster model
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In hamsters, retatrutide altered food preference with increased chow diet intake and decreased high fat/cholesterol diet and 10% fructose water intake.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH hamsters, retatrutide decreased intake of the high fat/cholesterol diet.

    In plain wordsIn obese hamsters, retatrutide decreased intake of the high fat and cholesterol diet.

    Peptide
    Retatrutide
    Outcome
    DecreaseHigh fat/cholesterol diet intake (hamsters)
    Study

    hamstern: not reported in source

    Diet-induced obese MASH hamster model
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In hamsters, retatrutide altered food preference with increased chow diet intake and decreased high fat/cholesterol diet and 10% fructose water intake.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH hamsters, retatrutide decreased intake of 10% fructose water.

    In plain wordsIn obese hamsters, retatrutide decreased intake of sugar water.

    Peptide
    Retatrutide
    Outcome
    DecreaseFructose water intake (hamsters)
    Study

    hamstern: not reported in source

    Diet-induced obese MASH hamster model
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In hamsters, retatrutide altered food preference with increased chow diet intake and decreased high fat/cholesterol diet and 10% fructose water intake.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH hamsters, retatrutide caused significant weight loss over 5 weeks of treatment.

    In plain wordsIn obese hamsters, retatrutide caused significant weight loss over 5 weeks.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody weight (hamsters)
    Study

    hamstern: not reported in source

    Diet-induced obese MASH hamster model
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 5 weeksAs given in this study (hamster).

    Source sentences

    Summary
    The significant weight loss was associated with a reduction in fat and lean mass, but the lean mass was not different after 5 weeks of treatment with no change in mineral bone density.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  16. 16AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH hamsters, weight loss with retatrutide was associated with a reduction in fat mass.

    In plain wordsIn obese hamsters, retatrutide weight loss came with lower fat mass.

    Peptide
    Retatrutide
    Outcome
    DecreaseFat mass (hamsters)
    Study

    hamstern: not reported in source

    Diet-induced obese MASH hamster model
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 5 weeksAs given in this study (hamster).

    Source sentences

    Summary
    The significant weight loss was associated with a reduction in fat and lean mass, but the lean mass was not different after 5 weeks of treatment with no change in mineral bone density.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  17. 17AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH hamsters, weight loss with retatrutide was associated with a reduction in lean mass, but lean mass was not different after 5 weeks of treatment.

    In plain wordsIn obese hamsters, weight loss with retatrutide came with lower lean mass, but lean mass was not different after 5 weeks.

    Peptide
    Retatrutide
    Outcome
    MixedLean mass (hamsters)
    Study

    hamstern: not reported in source

    Diet-induced obese MASH hamster model
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 5 weeksAs given in this study (hamster).

    Source sentences

    Summary
    The significant weight loss was associated with a reduction in fat and lean mass, but the lean mass was not different after 5 weeks of treatment with no change in mineral bone density.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  18. 18AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH hamsters, retatrutide caused no change in mineral bone density.

    In plain wordsIn obese hamsters, retatrutide did not change bone mineral density.

    Peptide
    Retatrutide
    Outcome
    No significant changeBone mineral density (hamsters)
    Study

    hamstern: not reported in source

    Diet-induced obese MASH hamster model
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 5 weeksAs given in this study (hamster).

    Source sentences

    Summary
    The significant weight loss was associated with a reduction in fat and lean mass, but the lean mass was not different after 5 weeks of treatment with no change in mineral bone density.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  19. 19AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH hamsters, retatrutide significantly reduced HOMA-IR.

    In plain wordsIn obese hamsters, retatrutide significantly lowered an insulin resistance index.

    Peptide
    Retatrutide
    Outcome
    DecreaseHOMA-IR (hamsters)
    Study

    hamstern: not reported in source

    Diet-induced obese MASH hamster model
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Retatrutide significantly reduced HOMA-IR, plasma triglycerides, and LDL-cholesterol levels.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  20. 20AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH hamsters, retatrutide significantly reduced plasma triglycerides.

    In plain wordsIn obese hamsters, retatrutide significantly lowered blood triglycerides.

    Peptide
    Retatrutide
    Outcome
    DecreasePlasma triglycerides (hamsters)
    Study

    hamstern: not reported in source

    Diet-induced obese MASH hamster model
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Retatrutide significantly reduced HOMA-IR, plasma triglycerides, and LDL-cholesterol levels.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  21. 21AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH hamsters, retatrutide significantly reduced LDL-cholesterol levels.

    In plain wordsIn obese hamsters, retatrutide significantly lowered LDL cholesterol.

    Peptide
    Retatrutide
    Outcome
    DecreaseLDL-cholesterol (hamsters)
    Study

    hamstern: not reported in source

    Diet-induced obese MASH hamster model
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Retatrutide significantly reduced HOMA-IR, plasma triglycerides, and LDL-cholesterol levels.
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  22. 22AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH hamsters, retatrutide did not reduce histopathological scoring.

    In plain wordsIn obese hamsters, retatrutide did not lower liver tissue damage scores.

    Peptide
    Retatrutide
    Outcome
    No significant changeHistopathological scoring (hamsters)
    Study

    hamstern: not reported in source

    Diet-induced obese MASH hamster model
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although retatrutide did not reduce histopathological scoring, there was a 50% reduction in hepatic triglyceride content (p < 0.01).
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
  23. 23AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese MASH hamsters, retatrutide reduced hepatic triglyceride content by 50%.

    In plain wordsIn obese hamsters, retatrutide lowered liver triglyceride content.

    Peptide
    Retatrutide
    Outcome
    DecreaseHepatic triglyceride content (hamsters)
    Study

    hamstern: not reported in source

    Diet-induced obese MASH hamster model
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    Hepatic triglyceride reduction
    50%
    retatrutide

    Source sentences

    Summary
    Although retatrutide did not reduce histopathological scoring, there was a 50% reduction in hepatic triglyceride content (p < 0.01).
    1 context sentence
    Summary · context
    Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.